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Abstract: Although a plethora of signaling pathways are known to drive the activation of hepatic
stellate cells in liver fibrosis, the involvement of connexin-based communication in this process
remains elusive. Connexin43 expression is enhanced in activated hepatic stellate cells and constitutes
the molecular building stone of hemichannels and gap junctions. While gap junctions support
intercellular communication, and hence the maintenance of liver homeostasis, hemichannels provide
a circuit for extracellular communication and are typically opened by pathological stimuli, such as
oxidative stress and inflammation. The present study was set up to investigate the effects of inhibition
of connexin43-based hemichannels and gap junctions on liver fibrosis in mice. Liver fibrosis was
induced by administration of thioacetamide to Balb/c mice for eight weeks. Thereafter, mice were
treated for two weeks with TAT-Gap19, a specific connexin43 hemichannel inhibitor, or carbenoxolone,
a general hemichannel and gap junction inhibitor. Subsequently, histopathological analysis was
performed and markers of hepatic damage and functionality, oxidative stress, hepatic stellate cell
activation and inflammation were evaluated. Connexin43 hemichannel specificity of TAT-Gap19 was
confirmed in vitro by fluorescence recovery after photobleaching analysis and the measurement of
extracellular release of adenosine-5′-triphosphate. Upon administration to animals, both TAT-Gap19
and carbenoxolone lowered the degree of liver fibrosis accompanied by superoxide dismutase
overactivation and reduced production of inflammatory proteins, respectively. These results support
a role of connexin-based signaling in the resolution of liver fibrosis, and simultaneously demonstrate
the therapeutic potential of TAT-Gap19 and carbenoxolone in the treatment of this type of chronic
liver disease.
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1. Introduction
Liver fibrosis is the result of a coordinated and conserved interplay between resident hepatic
cells, infiltrating inflammatory cells, and a number of paracrine and autocrine signals that lead to
the transdifferentiation of quiescent hepatic stellate cells (HSCs) into activated myofibroblast-like
counterparts [1,2]. Among these signaling cascades, inflammatory responses have gained increased
attention in the last few years. Hepatic macrophages, monocytes, natural killer T cells, and B cells
release a number of factors, such as reactive oxygen species, tumor necrosis factor α, platelet-derived
growth factor, transforming growth factor β, and other cytokines, which promote HSC activation [3,4].
Communication mechanisms that are participating in inflammation-promoting hepatic fibrosis have
been much less documented thus far. Direct intercellular communication is predominantly mediated
by gap junctions (GJs), which allow the flux of hydrophilic molecules up to ~1.5 kDa, such as
adenosine-5′-triphosphate (ATP) and ions between adjacent cells [5–7]. GJs arise from the docking of
two hemichannels from neighboring cells, each consisting of six connexin (Cx) proteins. While GJs
are involved in both physiological and pathological processes, hemichannels seem to be consistently
associated with stress conditions [8–10]. At present, more than 20 Cx species have been identified
in mammals and are named after their predicted molecular weight expressed in kDa. In rodent
and human liver, Cx43 is mainly harbored by nonparenchymal cells, including HSCs, Kupffer cells,
endothelial cells, and cholangiocytes, while Cx32, and to a lesser extent, Cx26, are abundantly expressed
by hepatocytes [9]. Hepatic Cx expression patterns undergo drastic changes in a broad range of liver
diseases, such as acute liver injury [11], hepatitis [12], cholestasis [13], cirrhosis [14], and hepatocellular
carcinoma [15]. Typically, an upregulation of Cx43 production is observed, while Cx32 expression is
negatively affected in liver disease [16]. In liver fibrosis, increased amounts of Cx43 have been detected
in activated HSCs [17] and activated Kupffer cells [18]. In addition, infiltrating immune cells also
contribute to the overall hepatic increase in Cx43 expression [18]. The role of enhanced Cx43 production,
in particular in activated HSCs, is not clear. In cultures of activated HSCs, the chemical inhibition of
Cx43-based GJs triggered a reduction in cellular contractibility [17]. Furthermore, Cx43 deficient-mice
developed excessive scarring with reduced inflammatory cell infiltration and hepatocellular damage in
liver fibrosis [19], suggesting a protective effect of Cx43-based signaling against hepatic scar formation,
as well as a role in the control of cell death and inflammation. The present study was set up to further
investigate the involvement of connexin43 signaling, through both hemichannels and GJs, in liver
fibrosis. In order to do so, a number of channel inhibitors were used, namely carbenoxolone (CBX) and
Gap19. While CBX is a general blocker of hemichannel and GJ signaling [20,21], Gap19 specifically
inhibits Cx43 hemichannels, thereby leaving GJs unaffected [22]. Since the target of Gap19 is located
intracellularly, it was linked to a HIV transactivator of transcription (TAT) sequence in order to facilitate
the passage through the plasma membrane [22,23].
2. Results
2.1. Effects of CBX and TAT-Gap19 on Gap Junctions and Hemichannels in Cultures of Primary
Rat Hepatocytes
To confirm the channel specificity of TAT-Gap19 in a hepatic system, fluorescence recovery after
photobleaching (FRAP) analysis and measurement of extracellular release of ATP were performed in
cultures of primary rat hepatocytes (Figure 1). In contrast to the in vivo situation, cultured primary rat
hepatocytes express Cx43-based hemichannels and gap junctions [24], which makes them a suitable
model to investigate TAT-Gap19 target specificity. Specifically, 24 h after cell plating, primary rat
hepatocytes were exposed to 50 µM CBX, 20 µM TAT-Gap19, or vehicle control for 30 min, 24 h and 48 h.
FRAP analysis revealed that GJ inhibition occurred when hepatocytes were exposed to CBX for 24 h
(p ≤ 0.01) and 48 h (p ≤ 0.05). In contrast, no modification in fluorescence recovery was noticed after
exposure to TAT-Gap19 measured on these time points (Figure 1A). To investigate the effects of both
CBX and TAT-Gap19 on hemichannel communication, a divalent-free (DF) buffer was used as a trigger
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of hemichannel opening followed by measurement of extracellular ATP amounts. To indirectly test the
stability, TAT-Gap19 was incubated at 37 ◦C for 0 min, 6 days, and 20 days in a classic incubator prior
to the cell culture testing. Primary rat hepatocytes were exposed to 50 µM CBX, 20 µM TAT-Gap19,
or vehicle control for 30 min. TAT-Gap19 was found to significantly inhibit extracellular ATP release
incubation at 37 ◦C for 6 days (p≤ 0.05) and 20 days (p≤ 0.05). CBX suppressed extracellular liberation
of ATP at all measured time points (p ≤ 0.01) (Figure 1B). These results confirm the selectivity of
TAT-Gap19 to block hemichannels and not GJs.
Int. J. Mol. Sci. 2018, 19, x FOR PEER REVIEW  3 of 17 
 
exposed to CBX for 24 h (p ≤ 0.01) and 48 h (p ≤ 0.05). In contrast, no modification in fluorescence 
recovery was noticed after exposure to TAT-Gap19 measured on these time points (Figure 1A). To 
investigate the effects of both CBX and TAT-Gap19 on hemichannel communication, a divalent-free 
(DF) buffer was used as a trigger of hemichannel opening fo lowed by easurement of xtrac llular 
ATP amounts. To indirectly tes  the stability, TAT-Gap19 was incubated at 37 °C for 0 min, 6 days, 
and 20 days in a classic incub tor prior to the cell culture t sting. Primary rat hepatocytes were 
exposed to 50 μM CBX, 20 μM AT-Gap19, or vehicle co trol for 30 m n. TAT-Gap19 was found to 
significa tly inhibit extracellular ATP release incubation at 37 °C for 6 days (p ≤ 0.05) nd 20 days  
(p ≤ 0.05). CBX suppressed extracellular liberation of ATP at all measured time points (p ≤ 0.01) (Figure 
1B). These resu ts confirm the s ectivity of TAT-Gap19 to block hemichannels and not GJs. 
 
Figure 1. Effects of carbenoxolone (CBX) and transactivator of transcription (TAT)-Gap19 on gap 
junctions (GJs), and hemichannels in cultures of primary rat hepatocytes. Primary rat hepatocytes 
were exposed to 50 μM CBX, 20 μM TAT-Gap19, or vehicle control. (A) GJ activity was measured 
through FRAP analysis after 30 min, 24 h and 48 h (n = 4, N = 4). (B) Hemichannel activity was 
determined by measurement of extracellular ATP release analysis after 30 min (n =3, N =6). TAT-
Gap19 was incubated at 37 °C for 0 min, 6 days, and 20 days in an incubator prior to functionality 
assessment. Results were analyzed by 1-way ANOVA followed by post hoc Bonferroni correction. 
Data were expressed as means ± SEM (* p ≤ 0.05; ** p ≤ 0.01). 
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of the area of collagen staining of liver sections with Sirius red and concomitant determination of
the percentage of collagen per section, while the activated HSC quantities were evaluated through
immunohistochemistry analysis of the area of alpha smooth muscle actin (α-SMA)-positive cells and
subsequent quantification of the percentage of the area of α-SMA-positive cells per section. Initially,
and as previously confirmed by others [25], no changes in the collagen deposition were observed as a
consequence of the withdrawal of the insult (Figure A1). TAT-Gap19-treated mice showed significantly
decreased collagen deposition (p ≤ 0.05), as well as lowed amounts of α-SMA-positive cells area
(p ≤ 0.01). A reduced collagen content (p ≤ 0.05) and lower quantities of α-SMA-positive cells area
(p ≤ 0.05) were equally found in CBX-treated mice (Figure 2), with no differences between the treated
groups. These data suggest that communication mediated by Cx43-based hemichannels and GJs play
a crucial role in the maintenance of the fibrotic response.
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injury in mice. Mice were administered TAA intraperitoneally for 8 weeks. Initially, mice (n = 15/group)
were administered with 100 mg TAA/kg body weight, followed by 10% weekly increments to the
utmost dose of approximately 200 mg TAA/kg body weight. Thereafter, an osmotic pump was
implanted in the peritoneal cavity, which ensured the release of 1 mg TAT-Gap19 or CBX/kg body
weight/ or saline for two weeks. (A) Serum levels of the necrotic cell death markers namely ALT and
AST, (B) Serum levels of the hepatic functionality markers albumin, conjugated and total bilirubin.
Results were analyzed by 1-way ANOVA followed by post hoc tests Bonferroni correction. Data were
expressed as means ± SEM (* p ≤ 0.05).
2.4. Effects of CBX and TAT-Gap19 on Anti-Oxidative Enzyme Activity after TAA-Induced Chronic Hepatic
Injury in Mice
Oxidative stress with generation of free radicals and lipid peroxidation constitutes a major
contributor to the progression of liver fibrosis [26]. For this reason, the activity of a number of
oxidative stress scavengers, including catalase, glutathione peroxidase (GPx), glutathione reductase
(GR), and superoxide dismutase (SOD), was assessed on liver tissue of fibrotic mice. TAT-Gap19-treated
mice showed increased SOD activity (p ≤ 0.0001) and no changes in catalase, GPx and GR activities.
Upon CBX treatment, the activity of GPx was significantly upregulated (p ≤ 0.05), with catalase, GR,
and SOD bei g unmodified (Figure 4). These resul s indicate enhanced anti-oxidative stress defence as
a result of TAT-Gap19 and CBX treatments.
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Figure 4. Effects of CBX and TAT-Gap19 on anti-oxidative enzyme activity after TAA-induced
chronic hepatic injury in mice. Mice were administered TAA intraperitoneally for 8 weeks. Initially,
mice (n = 8/group) were administered with 100 mg TAA/kg body weight, followed by 10% weekly
increments to the utmost dose of approximately 200 mg TAA/kg body weight. Thereafter, an osmotic
pump was implanted in the peritoneal cavity, which ensured the release of 1 mg TAT-Gap19 or CBX/kg
body weight/day or saline for two weeks. The activity of the anti-oxidant enzymes catalase, glutathione
peroxidase (GPx), glutathione reductase (GR), and superoxide dismutase (SOD) was evaluated in liver
tissue. Results were analyzed by 1-way ANOVA followed by post hoc Bonferroni correction. Data were
expressed as means ± SEM (* p ≤ 0.05; **** p ≤ 0.0001).
2.5. Effects of CBX and TAT-Gap19 on the Inflam atory Response after TAA-Induced Chronic Hepatic Injury
in Mice
Immune cells contribute to the liver fibrotic response by promoting hepatocellular damage and
HSC activation and also participate in fibrosis regression by extracellular matrix degradation [27].
Macrophages are believed to be the main mediators in both processes [28]. Accordingly, the number of
macrophages was evaluated through immunostaining of CD68 in liver tissue. CD68-positive cells were
mainly located in the sinusoids and in the surrounding area of the scar tissue. Importantly, TAT-Gap19
and CBX did not affect CD68-positive cell density or location (Figure 5).
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Further evaluation of inflammatory protein levels by semi-quantitative antibody array
analysis of liver tissue showed differential effects of TAT-Gap19 and CBX treatments (Figure A2).
TAT-Gap19-treated mice displayed a downregulation of lymphotactin (p ≤ 0.05) (Figure 6). In addition,
CBX-treated mice presented increased protein levels of eotaxin-2 (p ≤ 0.05) and Fas ligand (p ≤ 0.05),
whereas a reduction in interleukin 1α (p ≤ 0.01), 2 (p ≤ 0.05), and 4 (p ≤ 0.05) (IL1α/2/4),
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growth-regulated alpha protein (KC) (p ≤ 0.01), lipopolysaccharide-induced CXC chemokine
(LIX) (p ≤ 0.05), and thymus-expressed chemokine (TECK) (p ≤ 0.01) was observed (Figure 6).
Interestingly, upon comparison between CBX- and TAT-Gap19-related effects, granulocyte-macrophage
colony-stimulating factor (GM-CSF) was commonly modulated. In this context, TAT-Gap19-treated
mice showed an upregulation of GM-CSF (p ≤ 0.0001), whereas GM-CSF levels were downregulated
(p ≤ 0.01) in CBX-treated animals. These results point to the modulation of the inflammatory response
as a consequence of CBX treatment.
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hepatic injury in mice. Mice were administered TAA intraperitoneally for eight weeks. Initially,
mice (n = 4/group) were administered with 100 mg TAA/kg body weight, followed by 10% weekly
increments to the utmost dose of approximately 200 mg TAA/kg body weight. Thereafter, an osmotic
pump was implanted in the peritoneal cavity, which ensured the release of 1 mg TAT-Gap19 or
CBX/kg body weight/day or saline for t o weeks. After comparison between CBX versus saline
with TAT-Gap19 versus saline groups, three clusters of inflammatory proteins were defined, namely
(i) CBX-related effects; (ii) CBX- and AT-Gap19-related effects; and (iii) TAT-Gap19-related effects.
Data were analyzed by densitometric analysis. Then, background was subtracted, and results were
normalized i st the average of positive controls. Results were analyzed by 1-wa ANOVA followed
by post hoc Bonferroni co ection. Data were express d as mean ± SEM (* p ≤ 0.05; ** p ≤ 0.01;
**** p ≤ 0.0001). (GM-CSF, granulocyte-macrophage c lony-stimulating factor; IL1α/2/4, interleukin
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3. Discussion
In-depth knowledge of the molecular mechanisms that regulate liver fibrosis is of clinical
importance for the development of new therapies. In the last decade, it has become clear that Cx
hemichannels can act as pathological pores. Indeed, their inhibition counteracts the manifestation of
liver disease, including acute liver failure [29] and non-alcoholic steatohepatitis [30]. In the present
study, it was investigated whether this also holds true for liver fibrosis by using channel inhibitors.
In this regard, a number of short peptides have been introduced several years ago as selective tools
to block hemichannels, thereby leaving GJ activity unaffected [20,31]. Among those is TAT-Gap19,
which is designed to specifically inhibit Cx43-based hemichannels. The efficacy and specificity of
TAT-Gap19 to suppress Cx43 hemichannel opening has been previously demonstrated in astrocytes [23],
cardiomyocytes [22], and human gingival fibroblasts [32]. Our experiments showed that this is also the
case in primary rat hepatocytes. In these experiments, TAT-Gap19 incubated for extended periods of
time at 37 ◦C was used as a surrogate measurement of peptide stability for the in vivo study. It should
be noted that the effect exerted by the treatment with TAT-Gap19 and CBX is only attributed to channel
inhibition and not to altered Cx43 protein expression levels. Indeed, TAT-Gap19 was previously shown
to leave Cx43 expression unaffected [30]. Similar findings were reported for CBX [24]. Administration
of TAT-Gap19 as well as of the general GJ and hemichannel inhibitor CBX to liver fibrotic mice
decreased fibrotic areas in liver and reduced HSC activation, as evidenced by lowered amounts
of α-SMA-positive cells area. The mechanisms that are underpinning these effects are not clear.
Although CBX has the ability to abrogate GJ intercellular communication in activated HSCs [17],
studies based on in vitro-induced activation of primary HSCs showed that the effects exerted by
CBX are independent of GJ inhibition [33]. In addition, expression profiles of collagens type I and
III, as well as of α-SMA, are known to be affected by Cx43-based hemichannels in human gingival
fibroblasts [32]. These data suggest that Cx43-based hemichannels rather than their full channel GJ
counterparts are involved in the activation of HSCs. In addition, administration of TAT-Gap19 and
CBX did not alter the promotion of tissue damage, with the exception of the increased AST levels
observed upon CBX treatment. It should be stressed, however, that TAT-Gap19 and CBX released
from the osmotic pump in the abdominal cavity not only act on liver cells, but also may equally target
other organs and cells, especially those that are involved in inflammatory responses. Nevertheless,
no modification in the number of CD68-positive macrophages was observed following treatment with
TAT-Gap19 or CBX, yet production of inflammatory proteins was changed. Upon comparison, three
inflammatory protein clusters could be identified as differentially modulated, namely (i) CBX-related
effects; (ii) CBX- and TAT-Gap19-related effects; and (iii) TAT-Gap19-related effects. Specifically,
CBX elicited an upregulation of Fas ligand, which is an indicator of myofibroblast apoptosis [34].
This could explain the decreased number of activated HSCs upon CBX treatment. This coincided with
reduced amounts of IL1α, IL2, IL4, KC, LIX, and TECK. Among those, IL1α has been observed to
be decreased in autophagic macrophages [35], which contributes to the suppression of the fibrotic
response. During liver fibrosis, TECK is secreted by liver sinusoidal endothelial cells and favors HSC
migration as well as activation by macrophages [36], which further supports disease regression. Hence,
CBX-related signaling pathways might be involved in the modulation of immune responses-mediated
hepatic fibrosis. These results should; however, be considered with caution, since CBX also affects
the opening of many other channels, including pannexin1 channels [37], in addition to inhibiting
Cx-based hemichannels and GJs. In both the TAT-Gap19- and CBX-treated animal groups, an opposite
effect was observed on GM-CSF. While increased expression of GM-CSF, a cytokine that contributes
to the differentiation of monocytes into macrophages and dendritic cells [38,39], was observed upon
Cx43 hemichannel inhibition, a decreased production was seen following CBX administration. In the
TAT-Gap19-treated group, only lymphotactin was modified. An alternative anti-fibrotic mechanism
includes excessive oxidative stress. During activation, HSCs favor the anti-oxidant activity of GPx and
catalase to prevent cellular apoptosis in the presence of hydrogen peroxide [40]. Cx43 hemichannel
inhibition led to the accumulation of hydrogen peroxide due to SOD overactivation and the absence
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of effects on GPx and catalase activities, which may partially contribute to myofibroblast apoptosis.
This is in agreement with a previous report showing that Cx43 hemichannels provide a protective
mechanism against oxidative stress in osteocytes [41].
In summary, this study revealed important changes in communication mechanisms that were
mediated by Cx43 during liver fibrosis, whereby the effects mediated by GJs and hemichannels might
be linked to modifications in inflammatory and anti-oxidant defense, respectively. Future research
should determine a more specific role of Cx hemichannels and GJs in the different liver cells during
the fibrotic response.
4. Materials and Methods
4.1. Animals and Treatment
Male Balb/c mice were obtained from Jackson Laboratories (Bar Harbor, ME, USA). Animals were
housed in the animal facility of the School of Veterinary Medicine and Animal Science of the University
of São Paulo-Brazil. Mice were kept in a room with ventilation (i.e., 16–18 air changes/hour), relative
humidity (i.e., 45–65%), controlled temperature (i.e., 20–24 ◦C), and light/dark cycle 12:12, and were
given water and balanced diet (NUVILAB-CR1, Nuvital Nutrientes LTDA, Colombo, Brazil) ad libitum.
Liver fibrosis was induced by administration of TAA (Sigma-Aldrich, St. Louis, MO, USA), which
is a chemical that promotes a relatively stable fibrotic response with slow regression over time [25].
Mice were weighed (22± 4 g) and received three weekly doses of TAA diluted in physiological solution,
administered intraperitoneally for eight weeks, as previously described, with small modifications [42].
The initial dose of TAA was 100 mg/kg body weight followed by 10% weekly increments to the utmost
dose of approximately 200 mg TAA/kg body weight. Two days after final TAA dosing, mice were
treated daily with 1 mg TAT-Gap19 or CBX/kg body weight. Both of the compounds were administered
via an osmotic pump (Alzet, Cupertino, CA, USA) implanted in the peritoneal cavity for two weeks
(Figure 7). Control mice were treated in parallel with saline. Mice were euthanized after completion of
the treatment by exsanguination during sampling under isoflurane-induced anesthesia. Mouse blood,
collected by cardiac puncture, was drawn into a heparinized syringe and centrifuged for 10 min at
1503× g, and serum was stored at −20 ◦C. Mouse livers were excised, and fragments were fixed in
10% phosphate-buffered formalin or snap-frozen in liquid nitrogen with storage at −80 ◦C. This study
has been approved by the Committee on Bioethics of the School of Veterinary Medicine and Animal
Science of the University of São Paulo-Brazil (protocol number 9999100314, 13 October 2015), and all
of the animals received humane care according to the criteria outlined in the “Guide for the Care and
Use of Laboratory Animals”.
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Figure 7. Experimental design. Mice were administered intraperitoneally with TAA for eight weeks.
Initially, mice were administered with 100 mg TAA/kg body weight, followed by 10% weekly
increments to the utmost dose of approximately 200 mg TAA/kg body weight. Thereafter, an osmotic
pump was implanted in the peritoneal cavity, which ensured the release of 1 mg TAT-Gap19 or CBX/kg
body weight/day or saline for two weeks. Mice were euthanized after completion of the treatment and
blood and liver samples were collected for further analysis.
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4.2. Hepatocyte Rat Isolation and Cultivation
Male outbred Sprague-Dawley rats (Charles River Laboratories, Brussels, Belgium) were kept
under controlled environmental conditions with free access to food and water. Hepatocyte rat isolation
and cultivation procedures were performed, as previously detailed [30]. Briefly, rat hepatocytes
were isolated by use of a two-step collagenase perfusion method. After purification, cell viability
was assessed by trypan blue exclusion. Viable (≥85%) rat hepatocytes were plated at a density
of 0.56 × 105 cells per cm2 in William’s medium E (Invitrogen, Carlsbad, CA, USA) supplemented
with 7 ng/mL glucagon, 292 mg/mL L-glutamine, antibiotics (7.33 IU of sodium benzyl penicillin,
50µg/mL kanamycin monosulfate, 10µg/mL sodium ampicillin, and 50µg/mL streptomycin sulfate),
and 10% fetal bovine serum. After 4, 24 and 48 h, the cell culture medium was removed and replaced
by serum-free medium supplemented with 25µg/mL hydrocortisone sodium hemisuccinate and
0.5µg/mL insulin. This study was approved by the Ethical Committee for Animal Experiments of the
Vrije Universiteit Brussel (project number 14-210-1, 3 February 2015) and all animals received humane
care according to the criteria outlined in the “Guide for the Care and Use of Laboratory animals”.
4.3. TAT-Gap19 and CBX
TAT-Gap19 (YGRKKRRQRRR-KQIEIKKFK) was synthesized by Thermo Fischer (Schwerte,
Germany) at a purity of at least 90%. For in vitro and in vivo experiments, TAT-Gap19 was dissolved
in Hank’s balanced salt solution (Thermo Fisher Scientific, Waltham, MA, USA) buffered with 25 mM
Hepes (HBBS-Hepes) and saline, respectively. In the same line, CBX disodium salt (Sigma-Aldrich)
was dissolved in HBSS-Hepes and saline for cell culture and animal experiments, respectively.
4.4. Fluorescence Recovery after Photobleaching
FRAP analysis was performed 24 h after cell plating as previously described [24,30]. Cultured rat
hepatocytes were exposed to 50 µM CBX, 20 µM TAT-Gap19 or vehicle control for 30 min, 24 h and 48 h.
Fluorescence within a single cell was photobleached by one second spot exposure to 488 nm Argon
laser light, and dye influx from neighboring cells was recorded over the next 5 min with a 40× water
immersion objective (Nikon, Tokyo, Japan). Fluorescence in the bleached cell was expressed as the
percentage recovery relative to the prebleach level. At least four cells per culture dish were examined.
4.5. Measurement of Extracellular Adenosine-5′- Triphosphate
Extracellular ATP release was measured using a commercial luciferin/luciferase kit
(Sigma-Aldrich) as previously outlined [24]. TAT-Gap19 was pre-incubated at 37 ◦C for 0 min, 6 days,
or 20 days in an incubator (Galaxy 170S, New Bruswich, Hamburg, Germany). Thereafter, primary
rat hepatocyte cultures were exposed to 50 µM CBX, 20 µM TAT-Gap19 or vehicle control for 30 min.
These experiments were carried out 24 h after cell plating. After exposure, cultured rat hepatocytes
were washed with DF buffer (137 mM NaCl, 0.18 mM Na2HPO4·2H2O, 5.36 mM KCl, 0.44 mM
KH2PO4, 4 mM ethylene glycol tetra-acetic acid, 5.55 mM D-glucose, and 25 mM Hepes) to trigger
hemichannel opening or with HBBS-Hepes to mimic baseline conditions and incubated for 2.5 min to
DF buffer or HBSS-Hepes at room temperature. Then, ATP assay mix was added, and luminescence
was measured. ATP release was expressed as the percentage of ATP release triggered by the DF buffer.
4.6. Histopathological Liver Examination and Collagen Analysis
For microscopic evaluation, formalin-fixed liver fragments were embedded in paraffin and 5 µm
sections were stained with Sirius red for blinded evaluation of the liver, as previously described [19].
Morphometric analysis of Sirius red staining was performed in 10 randomly selected fields per section
from the left lobe of the mouse liver (20× objective). Semi-quantitative analysis of the fibrotic area
was performed with Image-Pro Plus 4.5 software (Media Cybernetics, Silver Spring, MD, USA) and
calculated by the formula [Area of fibrosis (%) = total fibrosis area/total area of the liver tissue].
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4.7. Immunohistochemistry
Immunoreactivity for α-SMA and CD68 was performed on liver mouse sections. Briefly, 5 µm
mouse liver sections were subjected to antigen retrieval at 120 ◦C for 5 min in a Pascal Pressure
Chamber (Dako Cytomation, Glostrup, Denmark) and blocked for 15 min. Then, slides were treated
with low-fat milk for 60 min and incubated in a humidified chamber overnight at 4 ◦C with 1/500
anti-α-SMA (Abcam, Cambridge, UK) or 1/2000 anti-CD68 (Abcam). Subsequently, slides were
incubated with a one-step polymer-horseradish peroxidase (EasyPath-Erviegas, São Paulo, Brazil) for
20 min, developed with 3, 3′-diaminobenzidine chromogen (Sigma-Aldrich), and counterstained with
Harris hematoxylin. Semi-quantitative analysis was performed using Image-Pro Plus 4.5 software
(Media Cybernetics) in 10 randomly selected fields (20× objective for α-SMA and 40× objective for
CD68) per section from the left lobe. Data analysis was based on the following calculations [α-SMA+
cells area (%) = α-SMA+ area/(total field area − vascular luminal area)] and [CD68+ density = CD68+
cells/total field area (mm2)].
4.8. Analysis of Serum Biochemical Parameters
Serum levels of ALT (IU/L), AST (IU/L), conjugated and total bilirubin (mg/dL) and albumin
(g/dL) were measured with an automated spectrophotometric Labmax 240 analyzer (Labtest
Diagnostica, Vista Alegre, Brazil).
4.9. Analysis of Hepatic Anti-Oxidant Enzymes
The activity of SOD, GPx, GR, and catalase was assayed in mouse liver tissue, as previously
described [43]. SOD activity was calculated by interpolation of the percentage of inhibition of
formazan generation using a linear regression curve prepared with SOD from bovine erythrocytes
(Sigma-Aldrich). GPx activity was continuously monitored at 340 nm absorbance over 4 min at 37 ◦C
by the detection of nicotinamide adenine dinucleotide phosphate. GPx activity was calculated by
linear regression using the percentage of inhibition promoted by GPx (Sigma-Aldrich). GR activity
was determined in the liver homogenate at an absorbance of 340 nm over 26 min at 37 ◦C by the
measurement of nicotinamide adenine dinucleotide phosphate oxidation. GR activity was calculated
based on linear regression using the percentage of inhibition triggered by GR (Sigma-Aldrich). Catalase
activity was continuously monitored in liver homogenate at 240 nm absorbance over 8 min at 30 ◦C
by the measurement of hydrogen peroxide. A standard curve was prepared using catalase enzyme
(Sigma-Aldrich). Enzymatic activity was expressed in U/mg protein.
4.10. Analysis of Liver Inflammatory Markers
Inflammatory markers were evaluated in hepatic homogenates from mouse using a mouse
inflammation antibody membrane array for 40 targets (ab133999, Abcam), following the
manufacturer’s instructions. Briefly, antibody spotted membranes were blocked during 30 min at
room temperature. Thereafter, blocked membranes were exposed to 250 µg protein/ml blocking buffer
overnight at 4 ◦C while shaking. Membranes were washed and incubated with biotin-conjugated
anti-cytokines for two hours at room temperature. Then, membranes were washed and exposed
to horseradish peroxidase-conjugated streptavidin for two hours at room temperature. Following
washing, proteins were detected by means of enhanced chemiluminescence and visualized by
ChemidocTM MP system (Bio-Rad, Hercules, CA, USA). Semi-quantitative results were obtained
after densitometric analysis. Thereafter, background was subtracted from each data point and results
were normalized against the positive controls provided by biotin-conjugated IgG and the results were
presented as relative signal intensity against saline.
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4.11. Statistical Analysis
The number of biological (n) and technical (N) repeats for each type of analysis varied and is
specified in the discussion of the results. All data were expressed as mean ± standard error of the
mean (SEM). Data distribution was determined by D’Agostino-Pearson normality test for large n or
Shapiro-Wilk normality test for low n. Thereafter, results were statistically processed by 1-way analysis
of variance (ANOVA) followed by post hoc Bonferroni correction using GraphPad Prism7 software
(version 7, GraphPad Software, La Jolla, CA, USA) with probability (p) values of less than or equal to
0.05 being considered as significant.
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Figure A1. TAA-induced liver fibrosis in mice before and after withdrawal of the insult. Mice were
administered TAA intraperitoneally for 8 weeks. Initially, mice were administered with 100 mg TAA/kg
body weight, followed by 10% weekly increments to the utmost dose of approximately 200 mg TAA/kg
body weight. Thereafter, mice were not treated with TAA for 2 weeks (10 weeks in total). Collagen
deposition was visualized by collagen fibers stained with Sirius red.
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controls. Results were analyzed by 1-way ANOVA followed by post hoc Bonferroni correction. Data 
were expressed as means ± SEM (* p ≤ 0.05; ** p ≤ 0.01; **** p ≤ 0.0001). (BLC, B lymphocyte 
chemoattractant; CD30L, tumor necrosis factor ligand superfamily member 8; Eotx, eotaxin; Frck, 
fractalkine, GCSF, granulocyte colony-stimulating factor; GM-CSF, granulocyte-macrophage colony-
stimulating factor; IFNγ, interferon γ; IL1α/2/7/4/6/9/10/12/13/17, interleukin 1 
alpha/2/7/4/6/9/10/12/13/17; ITAC, interferon-inducible T-cell α chemoattractant; KC, growth-
regulated α protein; LIX, lipopolysaccharide-induced CXC chemokine; Lymp, lymphotactin; MCP-1, 
monocyte chemoattractant protein 1; MCSF, macrophage colony-stimulating factor; MIG, monokine 
induced by gamma interferon; MIP1α/γ, macrophage inflammatory protein 1 alpha/gamma; Neg, 
negative; Pos, positive; RNTS, rantes; SDF-1, stromal cell derived factor 1; sTNF RI/II, soluble TNF 
receptor 1/2; TCA-3, T-cell activation protein 3; TECK, thymus-expressed chemokine; TIMP-1/-2, 
tissue inhibitor of metalloproteinase-1/-2; TNFα, tumor necrosis factor α). 
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